What is Arvinas, Inc. (ARVN) stock price today?

Arvinas, Inc. (ARVN) is currently trading at $7.64, up 1.73% today.

What is ARVN P/E ratio?

Arvinas, Inc.'s P/E ratio is 39.00. This is above the market average, reflecting high growth expectations.

What is ARVN return on equity (ROE)?

Arvinas, Inc.'s return on equity (ROE) is 1.91%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Arvinas, Inc.'s market cap?

Arvinas, Inc. has a market capitalization of $492.94M.

NASDAQ · Biotechnology

Arvinas, Inc. (ARVN) Stock

$7.64 +1.73% NASDAQ: ARVN Healthcare

Valuation

Metric	Value
Price	$7.64
Market Cap	$492.94M
P/E Ratio	39.00
P/B Ratio	0.85
P/S Ratio	1.51
EPS (TTM)	$0.00
52-Week High	$14.51
52-Week Low	$6.97
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	1.91%
ROA	1.38%
ROCE	-2.38%
Gross Margin	-43.73%
Operating Margin	-43.73%
Net Margin	2.94%
Debt/Equity	0.01
Current Ratio	4.90

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$54.0M	$131.0M	$79.0M	$263.0M	$263.0M
Operating Profit	$-188.0M	$-263.0M	$-401.0M	$-250.0M	$-115.0M
Net Profit	$-191.0M	$-282.0M	$-367.0M	$-199.0M	$-81.0M
EPS	$-3.82	$-5.31	$-6.62	$-2.77	$-1.28
Op Margin	-351.5%	-200.3%	-511.5%	-95.0%	-43.8%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$1.6B	$1.3B	$1.3B	$1.1B	$718.0M
Total Liabilities	$800.0M	$704.0M	$645.0M	$530.0M	$284.0M
Cash	$108.0M	$81.0M	$312.0M	$101.0M	$143.0M
Borrowings	$5.0M	$6.0M	$3.0M	$10.0M	$9.0M

Latest News

uniQure (QURE) Soars 78.4%: Is Further Upside Left in the Stock? Zacks · Jun 18, 2026 Rigel Pharmaceuticals Closes Licensing Deal for Breast Cancer Drug Veppanu MT Newswires · Jun 16, 2026 Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant) PR Newswire · Jun 16, 2026 Twist Bioscience (TWST) Surges 9.3%: Is This an Indication of Further Gains? Zacks · Jun 12, 2026 Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data MarketBeat · Jun 5, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$559.0M	$-273.0M	$-348.0M	$-259.0M	$-274.0M
Investing Cash Flow	$-1.3B	$236.0M	$201.0M	$33.0M	$406.0M
Financing Cash Flow	$14.0M	$0	$0	$0	$-92.0M
Net Cash Flow	$-476.0M	$-26.0M	$230.0M	$-217.0M	$42.0M
Free Cash Flow	$555.0M	$-280.0M	$-351.0M	$-261.0M	$-276.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-0.21
EV / EBITDA	135.17
FCF Yield	-43.67%
Quick Ratio	7.91
Interest Coverage	0.00
Return 1Y	3.18%
Return 3Y	-65.65%
Return 5Y	-88.70%

Ownership

Insiders Held7.91%

Institutions Held82.59%

Institutions Float Held89.68%

Institutional Holder	Shares	Report Date
Blackrock Inc.	6,797,584	2026-03-31
Vanguard Portfolio Management LLC	3,889,628	2026-03-31
Shaw D.E. & Co., Inc.	3,638,567	2026-03-31
Pfizer Inc	3,457,815	2026-03-31
Vanguard Capital Management LLC	2,689,362	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
CCCCC4 Therapeutics, Inc.	$3.16	+10.88%	-2.95	$349.39M	0.00%
FHTXFoghorn Therapeutics Inc.	$2.00	+0.50%	-2.11	$117.43M	0.00%
GLUEMonte Rosa Therapeutics, Inc.	$10.30	-0.19%	-4.82	$870.14M	0.00%
KYMRKymera Therapeutics, Inc.	$112.40	+2.84%	-34.00	$9.25B	0.00%
NRIXNurix Therapeutics, Inc.	$22.35	+0.63%	-6.61	$2.32B	0.00%

About Arvinas, Inc.

Arvinas, Inc. is led by CEO Randy Teel, employs 430 people, headquartered in US, publicly traded since 2018.

Arvinas, Inc. (ARVN) stock trades at $7.64 with a market capitalization of $492.94M. The stock is valued at a price-to-earnings (P/E) ratio of 39.00, price-to-book of 0.85, price-to-sales of 1.51. Over the past 52 weeks the stock has ranged between $6.97 and $14.51, and currently trades 47.3% below its 52-week high.

On profitability, Arvinas, Inc. generates a return on equity (ROE) of 1.91%, return on capital employed of -2.38%, an operating margin of -43.73%, a net profit margin of 2.94%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides